Amgen ends Aranesp price bundling practices in US
This article was originally published in Scrip
Executive Summary
Amgenis discontinuing US rebates to oncology clinics for the erythropoiesis-stimulating agent Aranesp (darbepoetin-alfa) and ending the controversial practice of tying price concessions for its neutropenia therapies to Aranesp purchases.